Importance The comparative clinical benefit of nonstatin therapies that reduce low-density
lipoprotein cholesterol (LDL-C) remains uncertain. Objective To evaluate the association …

With cardiovascular disease being the leading cause of morbidity and mortality worldwide,
effective and cost-efficient therapies to reduce cardiovascular risk are highly needed. Lipids …

Even at low-density lipoprotein cholesterol (LDL-C) goal, patients with cardiometabolic
abnormalities remain at high risk of cardiovascular events. This paper aims (i) to critically …

Since the discovery in the 1970s that plasma levels of high-density lipoprotein cholesterol
(HDL-C) are inversely associated with cardiovascular outcome, it has been postulated that …

BACKGROUND A growing body of evidence from epidemiological data, animal studies, and
clinical trials supports HDL as the next target to reduce residual cardiovascular risk in statin …

Notwithstanding the effectiveness of lowering LDL cholesterol, residual CVD risk remains in
high-risk populations, including patients with diabetes, likely contributed to by non-LDL lipid …

Background Treatment added to statin monotherapy to further modify the lipid profile may
include combination therapy to either raise the high-density lipoprotein (HDL) cholesterol …

Subnormal plasma levels of high-density lipoprotein cholesterol (HDL-C) constitute a major
cardiovascular risk factor; raising low HDL-C levels may therefore reduce the residual …

Foam cell formation and further accumulation in the subendothelial space of the vascular
wall is a hallmark of atherosclerotic lesions. Targeting foam cell formation in the …

Although statin therapy represents a cornerstone of cardiovascular disease (CVD)
prevention, a major residual CVD risk (60–70% of total relative risk) remains, attributable to …